Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06327932 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

StatusNot Yet Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 25, 2024 (before its estimated March 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or high-risk group Non-Muscle-Invasive Bladder Cancer (NMIBC).
Trial Details
NCT Number NCT06327932
Lead Sponsor Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Conditions
(from sponsor)		 Non-Muscle-Invasive Bladder Cancer
Related terms Non-Muscle Invasive Bladder Neoplasms
Enrollment 320 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov